+

WO1993010093A1 - Derives du 2-pyridinol et leur utilisation comme medicaments - Google Patents

Derives du 2-pyridinol et leur utilisation comme medicaments Download PDF

Info

Publication number
WO1993010093A1
WO1993010093A1 PCT/GB1992/002117 GB9202117W WO9310093A1 WO 1993010093 A1 WO1993010093 A1 WO 1993010093A1 GB 9202117 W GB9202117 W GB 9202117W WO 9310093 A1 WO9310093 A1 WO 9310093A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
group
hereinbefore defined
reacting
Prior art date
Application number
PCT/GB1992/002117
Other languages
English (en)
Inventor
Kenneth John Murray
Roderick Alan Porter
Hunter Douglas Prain
Brian Herbert Warrington
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to JP5509093A priority Critical patent/JPH07501069A/ja
Priority to EP92923485A priority patent/EP0613467A1/fr
Publication of WO1993010093A1 publication Critical patent/WO1993010093A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Definitions

  • the present invention relates to pyridinol derivatives, processes for their preparation, intermediates in their preparation, their use as medicaments and to pharmaceutical compositions comprising them.
  • the compounds of this invention are agonists of a cyclic AMP-dependent protein kinase (cA-PrK) (see J. Biol. Chem., 1989, 264, 8443 - 8446) and are of use in combatting such
  • cA-PrK cyclic AMP-dependent protein kinase
  • agonism is thought to be beneficial. They are likely to have anti-proliferative, anti-aggregatory, cholesterol-lowering, smooth muscle relaxant, positive lusitropic, anti-allergic or anti-inflammatory activities. They are likely to be useful in the treatment of
  • diastolic failure cancer, psoriasis, atheroschlerosis, thrombosis, re-stenosis, chronic reversible lung disease such as asthma and bronchitis, allergic disease such as allergic asthma, allergic rhinitis and urticaria or gut motility disorders such as irritable bowel syndrome.
  • R 0 is OH or a bioprecursor thereof
  • R 1 is A 0 CO 2 H, P (Z) (OH) (OR 2 ), SO 2 H or SO 3 H or a bioprecursor thereof
  • a 0 is CH 2 , CHF, CF 2 , CR 3 (OR 4 ) , CO or C(OR 5 ) (OR 6 ),
  • R 2 is phenyl, C 3-5 cycloalkyl, C 3-5 cycloalkylC 1-4 alkyl, or C 1-8 alkyl optionally substituted by C 1-4 alkoxy,
  • R 3 is H, methyl or ethyl
  • R 4 is H or C 1-3 alkyl
  • R 5 and R 6 are each C 1-3 alkyl or together form a 1,2- ethanediyl group or 1,3-propanediyl group,
  • Z is O or S
  • Ar is phenyl optionally substituted by one to three groups independently selected from C 1-6 alkyl, C 2-6 alkenyl,
  • Bioprecursors of the groups R 0 and R 1 are derivatives thereof which are convertible in vivo into the groups R 0 and R 1 .
  • R ⁇ is OR* 5 wherein R ⁇ is C 1-4 alkyl, arylC 1-4 alkyl (for example phenylC 1-4 alkyl such as benzyl), C 1-4 alkanoyl (for example acetyl), arylC 1-4 alkanoyl (for example phenyl C 1-4 alkanoyl such as benzoyl),
  • R 1 is A 0 CO 2 H
  • a suitable bioprecursor is A 0 CO 2 R 9 wherein R 9 is an ester-forming group.
  • R 1 is P (Z) (OH) (OR 2 )
  • a suitable bioprecursor is
  • Suitable O-protecting groups include pivaloyloxymethyl, propionyloxymethyl and pivalolyloxycarbonyloxymethyl.
  • bioprecursors of the groups R 0 and R 1 are those formed when R 1 and R 0 are linked together to form a cyclic structure such that R 1 -R 0 is A 1 CO 2 or A 2 OCH 2 O, in which : A 1 is CH 2 , CHF, CF 2 , CR 3 (OR 4 ), CO or C(OR 5 ) (OR 6 ),
  • a 2 is P(Z)OR 2 or CR 3 (CO 2 R 9 ), and
  • R 2 to R 6 , R 9 and Z are as hereinbefore defined.
  • R 0 is hydroxy or OR 8 , preferably hydroxy.
  • R 1 is A 0 CO 2 H or A 0 CO 2 R 9 .
  • R 1 is P (Z) (OH) (OR 2 ) or P(Z) (OR 2 ) 2 .
  • R 1 is SO 2 H or SO 3 H.
  • R 1 and R 0 are linked together such that R 1 -R 0 is A 1 CO 2 .
  • R 1 and R 0 are linked together such that R 1 -R 0 is A 2 OCH 2 O.
  • alkyl is meant both straight- and branched- chain alkyl.
  • C 1-6 polyfluoroalkyl is meant a C 1-6 alkyl group having at least one hydrogen replaced with fluoro, e.g. CF 3 or CF 2 CF 2 H.
  • R 2 is methyl, ethyl, propyl, butyl, pentyl, hexyl, 2-methoxyethyl, phenyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclopropylmethyl.
  • R 3 is H, methyl or ethyl, preferably H or methyl.
  • R 4 is H, methyl, ethyl or propyl, preferably H or methyl.
  • R 5 and R 6 are independently methyl, ethyl or propyl, preferably together they form a 1,2-ethanediyl group.
  • Z is O.
  • R 9 is C 1-4 alkyl optionally substituted by hydroxy, e.g. 2-hydroxyethyl or arylC 1-4 alkyl (for example
  • phenylC 1-4 alkyl such as benzyl
  • Ar is phenyl optionally mono-substituted by a group as hereinbefore defined, for example in the 2,3, or 4
  • Ar is phenyl di-substituted by any groups as
  • Ar is phenyl trisubstituted by any groups as
  • C 2-6 alkenyl, C 1-6 alkoxy or halo examples include methoxy, ethoxy, propoxy, butoxy, or pentyloxy.
  • C 1-6 alkyl examples include methyl, ethyl, propyl, butyl, isobutyl or pentyl.
  • halo examples include fluoro, chloro, bromo or iodo.
  • Particular compounds of this invention include : ethyl [6-(3-bromophenyl)-2-oxo-1,2-dihydro-3-pyridyl]- phosphonate, ethyl [6-(4-bromophenyl)-2-oxo-1,2-dihydro-3-pyridyl]- phosphonate,
  • This invention covers all tautomeric, geometric and optical isomeric forms of compounds of formula (1).
  • R 0 is hydroxy the compound can exist in its keto tautomeric form :
  • Compounds of the formula (1) can form pharmaceutically acceptable base addition salts with metal ions, such as alkali metals for example sodium or potassium, or with an ammonium ion.
  • metal ions such as alkali metals for example sodium or potassium, or with an ammonium ion.
  • acceptable salts may be administered in standard manner for the treatment of the indicated diseases, for example orally, sublingually, parenterally, transdermally, rectally, via inhalation or via buccal administration.
  • an oral liquid formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, glycerine or water with a flavouring or colouring agent.
  • a liquid carrier for example, ethanol, glycerine or water with a flavouring or colouring agent.
  • any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include starch, celluloses, lactose, sucrose and magnesium stearate.
  • any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell.
  • any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be
  • aqueous gums celluloses, silicates or oils and are incorporated in a soft gelatin capsule shell.
  • Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil or solubilising agent, for example
  • polyethylene glycol polyvinylpyrrolidone, lecithin,
  • 2-pyrrolidone 2-pyrrolidone, cyclodextrin, arachis oil, or sesame oil.
  • a typical suppository formulation comprises a compound of formula (1) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogues.
  • Typical transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream,
  • compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane, or are in the form of a powder for insufflation.
  • composition is in unit dosage form, for example
  • Each dosage unit for oral administration contains suitably from 0.001 mg/Kg to 30 mg/Kg, and preferably from 0.005 mg/Kg to 15 mg/Kg, and each dosage unit for parenteral
  • administration contains suitably from 0.001 mg/Kg to 10 mg/Kg, of a compound of formula (1) or a pharmaceutically acceptable salt thereof calculated as the free acid.
  • the daily dosage regimen for oral administration is suitably about 0.001 mg/Kg to 120 mg/Kg, of a compound of formula (1) or a pharmaceutically acceptable salt thereof calculated as the free acid.
  • the daily dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg, for example about 0.005 mg/Kg to 10 mg/Kg, of a compound of the formula (1) or a pharmaceutically acceptable salt thereof calculated as the free acid.
  • the active ingredient may be administered as required for example from 1 - 8 times a day or by infusion.
  • the compositions of the invention are agonists of a cA-PrK and are of use in combatting such conditions where such agonism is thought to be beneficial. Such conditions can be treated by administration orally, sublingually topically, rectally, parenterally or by
  • inhalation For administration by inhalation dosages are controlled by a valve, are administered as required and for an adult are conveniently in the range 0.1 - 5.0 mg of a compound of the formula (1) or a pharmaceutically acceptable salt thereof.
  • the compounds of this invention may be co-administered with other pharmaceutically active compounds, for example in combination, concurrently or sequentially.
  • the compounds of this invention and the other active compound or compounds are formulated in a single pharmaceutical
  • bronchodilators such as sympathomimetic amines for example isoprenaline, isoetharine, sulbutamol, phenylephrine and ephedrine or xanthine derivatives for example
  • anti-allergic agents for example disodium cromoglycate, histamine H 1 -antagonists
  • drugs used in the treatment of cancer such as those which inhibit the synthesis of or inactivate DNA, for example methotrexate, fluoracil, cisplatin, actinomycin D, anti-atherschlerotic agents for example cholesterol lowering drugs such as HMGCoA reductase inhibitors, bile acid sequestrants, drugs for the treatment of psoriasis, for example retinoids, anthralin, anti-inflammatories for example cortiscosteroids, non-steroid anti-inflammatories such as aspirin,
  • antithrombotics for example dipyridamole, or fibrinolytic agents.
  • the present invention provides a process for the preparation of compounds of the formula (1) or pharmaceutically acceptable salts thereof, which process comprises : a) for compounds wherein R 1 is A 0 CO 2 H or A 0 CO 2 R 9 and : i) A 0 is CR 3 (OR 4 ),
  • R 11 is methyl and Ar is as hereinbefore defined, with a compound of the formula (3) :
  • R 12 is CR 3 (OH)CO 2 R 9 and R 3 , R 9 , R 11 , and Ar are as hereinbefore defined and thereafter optionally reacting with a C 1-3 alkylating agent to form the corresponding compound wherein R 12 is CR 3 (OC 1-3 alkyl)CO 2 R 9 , ii) A 0 is CO,
  • R 12 is COCO 2 R 9 and R 9 , R 11 , and Ar are as hereinbefore defined with a C 1-3 alcohol, 1,2-ethanediol or 1,3-propanediol to form the corresponding compound wherein R 12 is C(OR 5 ) (OR 6 )CO 2 R 9 , vi) A 0 is CF 2 ,
  • CH(OH)CO 2 R 9 and R 9 , R 11 , and Ar are as hereinbefore defined with a fluorinating agent to form the corresponding compound wherein R 12 is CHFCO 2 R 9 , and thereafter optionally : o converting the group OR 11 into OH ° converting the group A 0 CO 2 R 9 into A 0 CO 2 H; or b) for compounds wherein R 1 is CH 2 CO 2 H,
  • R 13 is acetyl and Ar is as hereinbefore defined into the corresponding compound wherein R 13 is CH 2 CO 2 H; or c) for compounds wherein R 1 is CH(OR 4 )CO 2 H reacting a compound of the formula (4) wherein R 12 is -CH(OH)CN with a C 1-3 alkylating agent and/or converting the group CN into
  • R 1 is P(O) (OH) (OR 2 ), hydrolysing a compound of the formula (6) wherein R 13 is P (O) (OR 2 ) 2 and R 2 , and Ar are as hereinbefore defined; or e) for compounds wherein R 1 is P (S) (OH) (OR 2 ) , converting a compound of the formula (6) wherein R 13 is P (O) (NHR 14 ) (OR 2 ) and R 14 is phenyl or C 1-4 alkyl and Ar is as hereinbefore defined into the corresponding compound wherein R 13 is
  • R b is a group R 1 as hereinbefore defined or a
  • R a is R 0 or OR 11 as hereinbefore
  • L is a leaving group with a compound of the formula (8): ArB (OH) 2 (8) or a chemical equivalent thereof wherein Ar is as
  • a compound of the formula (2) is reacted with a strong base such as lithium diisopropylamide, or a C 1-4 alkyl lithium or aryl lithium such as mesityl lithium in an organic solvent such as tetrahydrofuran, diethylether or
  • the strong base may be formed in situ, for example by the addition of a C 1-4 alkyl lithium e.g. methyllithium followed by a catalytic quantity of diisopropylamine.
  • a suitable compound of the formula (3) is ethylpyruvate, or ethyl
  • glyoxylate or a chemical equivalent thereof and a suitable compound of the formula (5) is diethyloxalate.
  • a compound of the formula (4) wherein R 12 is CR 3 (OH)CO 2 R 9 is suitably reacted with a C 1-3 alkylating agent such as
  • iodomethane, iodopropane or dimethylsulphate in the presence of a base such as sodium hydride or potassium hydroxide in an organic solvent such as dimethylformamide or
  • dimethylsulphoxide at elevated (e.g. 30 - 80°C) or preferably ambient temperature to form the corresponding compound wherein R 12 is CR 3 (OC 1-3 alkyl)CO 2 R 9 .
  • R 12 is CR 3 (OC 1-3 alkyl)CO 2 R 9 .
  • potassium hydroxide is used as base the CO 2 R 9 group may be directly converted to carboxy.
  • a compound of the formula (4) wherein R 12 is COCO 2 R 9 is suitably reacted with a reducing agent such as sodium borohydride, or diisobutylaluminium hydride in an organic solvent such as dichloromethane, a C 1-4 alcohol e.g. ethanol, or acetic acid or mixtures thereof at ambient or elevated temperature (e.g. 30 - 80°C), or with cooling (e.g. 0 - 5°C) to form the corresponding compound wherein R 12 is
  • COCO 2 R 9 is suitably reacted with a reducing agent such as a zinc amalgam in hydrochloric acid in the absence of a solvent or in a solvent such as ethanol, acetic acid or dioxan and hydrogen chloride gas at ambient or elevated temperature (e.g. 40-100°C) to form the corresponding compound wherein R 12 is CH 2 CO 2 H. Under these reaction conditions the CO 2 R 9 group is converted to carboxy.
  • a reducing agent such as a zinc amalgam in hydrochloric acid in the absence of a solvent or in a solvent such as ethanol, acetic acid or dioxan and hydrogen chloride gas at ambient or elevated temperature (e.g. 40-100°C)
  • a compound of the formula (4) wherein R 12 is COCO 2 R 9 is suitably reacted with a C 1-3 alcohol, 1,2-ethanediol or 1,3- propanediol in the presence of an acid catalyst such as paratoluenesulphonic acid, concentrated sulphuric acid or anhydrous hydrogen chloride, at ambient or elevated
  • CHOHCO 2 R 9 is suitably reacted with a fluorinating agent such as diethylaminosulphur trifluoride in an organic solvent such as a halohydrocarbon or an ether, such as glyme, or THF at ambient or elevated temperature (e.g. 30-60°C) to form the corresponding compound where R 12 is CF 2 CO 2 R 9 or CHFCO 2 R 9 respectively.
  • a fluorinating agent such as diethylaminosulphur trifluoride
  • an organic solvent such as a halohydrocarbon or an ether, such as glyme, or THF at ambient or elevated temperature (e.g. 30-60°C)
  • R 12 is CF 2 CO 2 R 9 or CHFCO 2 R 9 respectively.
  • a compound of the formula such as wherein OR 11 is methoxy can suitably be converted to the corresponding compound wherein OR 11 is hydroxy by reaction with sodium iodide and
  • a compound of the formula (4) wherein R 12 is A 0 CO 2 R 9 can suitably be converted to the corresponding compound wherein R 12 is A 0 CO 2 H by reaction with an aqueous base such as sodium or potassium hydroxide at ambient or elevated temperature (e.g. 40 - 120°).
  • aqueous base such as sodium or potassium hydroxide at ambient or elevated temperature (e.g. 40 - 120°).
  • This method is particularly suitable for preparing compounds of the formula (1) wherein R 0 is methoxy since the OR 11 group is not hydrolysed.
  • Another hydrolysis method utilises aqueous acid such as concentrated
  • hydrochloric acid at an elevated temperature e.g. 40 - 120°C which provides directly compounds of the formula (1) wherein R 0 is hydroxy and R 1 is A 0 CO 2 H.
  • hydrolysis with an aqueous base such as sodium hydroxide at elevated temperature, preferably at the reflux temperature of the reaction mixture.
  • aqueous base such as sodium hydroxide
  • a compound of formula (4) where R 12 is -CH(OH)CN is reacted with a C 1-3 alkylating agent as hereinbefore described followed by reaction with aqueous mineral acid such as 5N hydrochloric acid at ambient or elevated temperature preferably at refux in order to prepare the corresponding compound where R 12 is CH(OC 1-3 alkyl) CO 2 H.
  • aqueous mineral acid such as 5N hydrochloric acid at ambient or elevated temperature preferably at refux
  • the alkylation can be omitted if the corresponding compound where R 12 is CH(OH)CO 2 H is desired.
  • the OR 11 group may be converted to hydroxy. If not and if desired this group can be converted to hydroxy as
  • a compound of the formula (4) wherein R 12 is -CH(OH)CN can be prepared by reacting the corresponding compound wherein R 12 is -CHO with a source of cyanide such as potassium cyanide in the presence of acid such as hydrochloric acid preferably at ambient temperature.
  • a compound of the formula (4) or (6) where R 12 or R 13 is CHO is suitably prepared by reacting the corresponding compound wherein R 12 or R 13 is cyano with a suitable reducing agent such as diisobutylaluminium hydride followed by aqueous acidic work-up.
  • P (O) (OR 2 ) 2 is hydrolysed by reaction with an aqueous base such as sodium hydroxide optionally in a cosolvent such as a C 1-4 alcohol at an elevated temperature (e.g. 40-100°C), preferably at the reflux temperature of the reaction mixture.
  • an aqueous base such as sodium hydroxide
  • a cosolvent such as a C 1-4 alcohol
  • dimethoxyethane at ambient or elevated temperature (e.g. 40 - 100°C) followed by reaction with carbon disulphide.
  • a compound of the formula (7) is reacted with a compound of the formula (8) in the presence of 1-50 mole %, preferably 2-10 mole %, of a palladium catalyst and a base such as triethylamine, sodium bicarbonate, or aqueous sodium carbonate and optionally lithium chloride in an organic solvent such as dimethylformamide, dimethoxyethane,
  • L 1 is halo for example iodo, bromo or chloro or a trifluoromethanesulphonate.
  • the OR 11 group can be converted to hydroxy as hereinbefore described for compounds of formula (4).
  • palladium catalysts that can be used include: tetrakis (triphenylphosphine) palladium (Pd[PPh 3 ] 4 ),
  • a chemical equivalent of a compound of the formula (8) is meant a reagent that can couple the Ar group onto the pyridyl ring of a compound of the formula (7).
  • aryl stannanes can be used, such as ArSnMe 3 which can suitably be prepared by reacting a suitable aryl halide (such as ArBr or Arl) with a base such as t-butyl lithium followed by reaction with a trimethyl tin halide (e.g. Me 3 SnCl).
  • a suitable aryl halide such as ArBr or Arl
  • a base such as t-butyl lithium
  • a trimethyl tin halide e.g. Me 3 SnCl
  • the aryl halide can be reacted with Me 3 SnSnMe 3 in the presence of a palladium catalyst as hereinbefore described to prepare a suitable aryl stannane.
  • R b is a group R
  • R 1 An example of a precursor for R 1 is when R b is hydrogen.
  • reaction of a compound of the formula (7) with a compound of the formula (8) or a chemical equivalent thereof results in a compound of the formula (2) or a
  • R 1 include CN, CHO or COMe.
  • Reaction of a compound of the formula (7) wherein R b represents such a precursor with a compound of the formula (8) or a chemical equivalent thereof results in a compound of the formula (4) or a compound of the formula (6) wherein R 12 or R 13 is CN, CHO or COMe.
  • Such compounds can be converted to compounds of the formula (1) as herein described.
  • a compound of the formula (1) wherein R 1 is A 0 CO 2 H can be converted to the corresponding compound wherein R 1 is A 0 CO 2 R 9 by reaction with a compound R 9 OH wherein R 9 is as hereinbefore defined.
  • a compound of the formula (1) wherein R 0 is OH can be
  • R 0 is OR 8 by reaction with R 8 L 2 wherein R 8 is as hereinbefore defined and L 2 is a leaving group such as halo e.g. bromo, chloro, iodo. If desired a compound of the formula (1) wherein R 1 is
  • O-protecting agent in standard manner.
  • the O-protecting agent in standard manner.
  • a compound of the formula (1) wherein R 1 -R 0 is A 1 CO 2 is suitably prepared by heating a compound of the formula (1) wherein R 1 is A 1 CO 2 H and R 0 is OH with a dehydrating agent such as acetic anhydride, at an elevated temperature (e.g. 40 - 200°C), preferably at the reflux temperature of the
  • a compound of the formula (1) wherein R 1 -R 0 is A 2 OCH 2 O is suitably prepared by reacting a compound of the formula (1) wherein R 1 is A 2 OH and R 0 is OH with a dihalomethane such as diiodo- or dibromomethane in the presence of silver carbonate in an organic solvent such as dimethylformamide at an
  • elevated temperature e.g. 40 - 120°C.
  • a compound of the formula (2) is suitably prepared by
  • dimethylformamide dimethylacetal in dimethylformamide or trimethylphosphite at an elevated temperature e.g. 40 -
  • a compound of the formula (6) wherein R 13 is cyano, acetyl or hydrogen is suitably prepared by reaction of a compound of the formula (9) :
  • ArCOCH CHL 3 (9) with a compound of the formula (10) : R 15 CH 2 CONH 2 (10) wherein R 15 is cyano, acetyl or hydrogen respectively, and L 3 is a displaceable group and Ar is as hereinbefore defined.
  • L 3 in a compound of the formula (9) is hydroxy or a derivative thereof for example L 3 is protected hydroxy such as silyloxy, an acid residue (for example C 1-6 alkanoyloxy) or an ether residue (for example methoxy or ethoxy).
  • L 3 is a secondary amino group, for example di-C 1-6 alkylamino such as dimethylamino or a cyclic amino group such as piperidino, pyrrolidino or morpholino.
  • L 3 is hydroxy or dimethylamino.
  • an alkali metal (e.g. sodium) salt of a compound of the formula (9) wherein L 3 is hydroxy is treated with a compound of the formula (10) under mildly alkaline aqueous conditions, for example in water in the presence of
  • a compound of the formula (9) wherein L 3 is a secondary amino group, for example dimethylamino is treated with a compound of the formula (10) in a suitable solvent such as dimethylformamide, a C 1-4 alkanol or pyridine at an elevated temperature e.g. (30 - 200°C), preferably at the reflux temperature of the reaction mixture optionally in the presence of a base such as pyridine or an alkali metal
  • alkoxide e.g. sodium methoxide
  • L 4 is ethoxy or methoxy.
  • a solution of a compound of the formula (11) and a compound of the formula HCOL 3 in a suitable organic solvent such as diethyl ether is treated with a suitable base such as an alkali metal alkoxide, e.g. sodium methoxide at ambient temperature.
  • a suitable base such as an alkali metal alkoxide, e.g. sodium methoxide at ambient temperature.
  • the resulting reaction mixture is preferably extracted with water and the aqueous extract which contains the alkali metal salt of a compound of the formula (9) wherein L 3 is hydroxy is then treated with a compound of the formula (10) as
  • N,N-dimethylformamide dimethyl or diethyl acetal N,N-dimethylformamide dimethyl or diethyl acetal
  • a compound of the formula (11) can be reacted with a compound of the formula HC(L 3 ) 3 (for example tris dimethylaminomethane).
  • a compound of the formula (6) wherein R 13 is acetyl can also be prepared by reacting a compound of the formula (6) wherein R 13 is cyano with methyl lithium followed by aqueous acidic work up with for example hydrochloric acid.
  • a compound of the formula (6) wherein R 13 is hydrogen can also be prepared by heating a compound of formula (11) as hereinbefore defined with a C 1-4 alkyl propiolate (such as methyl propiolate) and ammonia in a solvent such as a
  • a compound of formula (4) wherein R 12 is cyano is suitably prepared by reacting the anion of a compound of formula (2) wherein Ar and R 11 are as hereinbefore defined with
  • a compound of the formula (6) wherein R 13 is cyano or acetyl and Ar is as hereinbefore defined can be suitably prepared by reaction of a compound of formula (4) wherein R 12 is cyano or acetyl and R 11 and Ar are as hereinbefore defined with a demethylating agent such as sodium
  • iodide/chlorotrimethylsilane in the absence of solvent or in an organic solvent such as acetonitrile or chloroform at an elevated temperature (e.g. 40 to 100°C) or at ambient
  • a compound of the formula (6) wherein R 13 is P (O) (OR 2 ) 2 can be prepared by treating a compound of the formula (2) wherein R 11 is P (O) (OR 2 ) 2 with a strong base such as lithium
  • a compound of the formula (2) wherein R 11 is P (O) (OR 2 ) 2 is suitably prepared by treating a compound of the formula (6) wherein R 13 is hydrogen with a compound of the formula (12):
  • L 5 is halo, for example chloro or bromo.
  • a compound of formula (2) wherein R 11 is P (O) (OR 2 ) 2 can also be prepared by treating a compound of the formula (6) wherein R 13 is hydrogen with a compound of the formula (13): HP (O) (OR 2 ) 2 (13) wherein R 2 is as hereinbefore defined in the presence of an amine base such as triethylamine, and carbon tetrachloride.
  • a compound of the formula (6) wherein R 13 is P (O) (OR 2 ) 2 is suitably prepared by treating a compound of the formula (6) wherein R 13 is hydrogen with a compound of the formula (12) in the presence of a strong base such as lithium diisopropylamide in an organic solvent such as
  • a compound of formula (6) wherein R 13 is hydrogen is suitably prepared by demethylating a compound of formula (2) as hereinbefore defined.
  • a compound of formula (2) is treated with boron tribromide in an organic solvent such as dichloromethane or toluene with cooling (e.g. -80 to 10°C) followed by ambient temperature and aqueous work-up.
  • a compound of formula (2) is treated with sodium iodide and chlorotrimethylsilane at ambient or elevated temperature (e.g. 40-80°C) conveniently ambient temperature in a solvent such as acetonitrile or dichloromethane.
  • a compound of the formula (6) wherein R 13 is P (O) (NHR 14 ) (OR 2 ) can be prepared by reaction of a compound of the formula (6) wherein R 13 is P (O) (OH) (OR 2 ) with carbon tetrachloride, triphenylphosphine and aniline or a C 1-4 alkylamine in an organic solvent such as pyridine at ambient temperature or with cooling (e.g. -10 to 5°C).
  • a compound of the formula (6) where R 13 is P (O) (OH) (OR 2 ) can be reacted with dimethylformamide and oxalyl chloride in an organic solvent such as a halo hydrocarbon e.g. dichloromethane at ambient temperature, followed by reaction with aniline or a C 1-4 alkylamine preferably with cooling (-10 to 5°C).
  • R a and L 1 are as hereinbefore defined using similar methods to those described for preparing compounds of the formula (1).
  • a compound of the formula (7) wherein R b is P (O) (OR 2 ) 2 can be prepared by reacting a compound of the formula (14) wherein R a is OH with a compound of the formula (12) or (13) in similar manner to the reaction of a compound of the formula (6) wherein R 13 is hydrogen with a compound of the formula (12) or (13). If desired the group R a can then be converted to OMe.
  • a compound of the formula (14) where R a is OMe can be treated in the presence of a strong base with a compound of the formula (3), a compound of the formula (5), sulphuryl chloride, sulphur dioxide or dimethylformamide to prepare a compound of the formula (7) wherein R b is CR 3 (OR 4 )CO 2 R 9 , COCO 2 R 9 , SO 3 H, SO 2 H or CHO respectively in similar manner to the corresponding reaction with a compound of the formula (2) as hereinbefore described.
  • Particularly suitable as a strong base is lithium tetramethyl piperidide.
  • a compound of the formula (8) is suitably prepared by
  • Ar-L 6 (15) wherein L 6 is bromo or iodo and Ar is as hereinbefore defined with a tri-C 1-4 alkylborate such as trimethyl, tri-isopropyl or tri-n-butyl borate in an organic solvent such as diethyl ether or tetrahydrofuran with cooling (e.g. - 80-10°C).
  • a tri-C 1-4 alkylborate such as trimethyl, tri-isopropyl or tri-n-butyl borate in an organic solvent such as diethyl ether or tetrahydrofuran with cooling (e.g. - 80-10°C).
  • the Ar group in compounds of the formula (2), (4), (6), (11) or (15) preferably (2), (4) or (11) may be appropriately functionalised by methods of aromatic substitution known in the art.
  • a bromo group may be introduced into a suitably substituted phenyl ring (eg. disubstituted in the 2- and 4-positions by electron-donating groups such as
  • a nitro group can be introduced into a phenyl ring by reaction with a suitable nitrating agent, such as nitronium tetrafluoroborate.
  • a suitable nitrating agent such as nitronium tetrafluoroborate.
  • Such a group can be readily hydrogenated to an amino group which if desired can be converted to a NHCOR 7 group by reaction with LCOR 7 wherein L is a leaving group and R 7 is as hereinbefore defined.
  • Suitable examples of the reagent LCOR include acid halides (L is halo eg. chloro or bromo) or acid anhydrides (L is OCOR 7 ).
  • Suitable functionalisations include the introduction of an allyl group ortho to a hydroxy substituent on a phenyl ring by reaction with an allyl halide, eg. bromide, to form an allyloxy derivative which on heating undergoes a Claisen rearrangement to form an ortho allyl hydroxy derivative.
  • the hydroxy group can in turn be functionalised, eg. by reaction with a C 1-6 alkyl halide to form a C 1-6 alkoxy group.
  • an allyl group can be converted to an E-1-propenyl group by reaction with a strong base, such as sodium
  • E-1-propenyl group can be cleaved to a formyl group by
  • N-methylmorpholine-N-oxide in the presence of a catalyst such as osmium tetroxide to form a 1,2, dihydroxypropyl group which on reaction with an oxidising agent such as sodium periodate forms the formyl group.
  • a catalyst such as osmium tetroxide
  • an oxidising agent such as sodium periodate
  • the E-1-propenyl group can be converted directly to a formyl group by reaction with a mixture of osmium tetroxide and sodium periodate or by reaction with ozone.
  • a formyl group can in turn be further functionalised, for example it can be converted to a
  • hydroxymethyl group by reaction with a suitable reducing agent such as sodium borohydride, the hydroxymethyl group then being reacted further, eg. with a C 1-6 alkyl halide to form a C 1-6 alkoxymethyl group.
  • R 7 is as hereinbefore defined.
  • Pharmaceutically acceptable base addition salts of the compounds of the formula (1) may be prepared by standard methods, for example by reacting a solution of the compound of the formula (1) with a solution of the base.
  • Type II cA-PrK was prepared from the cardiac muscle of a cow. The supernatant from a muscle homogenate (3 mis of 10 mM potassium phosphate, 1 mM EDTA per g tissue) was applied to a column of DEAE-cellulose equilibrated with the homogenisation buffer and the type II cA-PrK was eluted with homogenisation buffer containing 350 mM sodium chloride (Rannels et al., 1983, Methods Enzymol., 99, 55-62). Type II cA-PrK was assayed for phosphotransferase activity by incubating the enzyme at 30°C for 5 minutes with
  • phosphocellulose papers The concentration of compound required to give 10% phosphotransferase activation is given as the EC 10 ( ⁇ M).
  • the compounds of Examples 1 to 7 had EC 10 values in the range 1 to 30 ⁇ M.
  • IC 50 concentration of compound which caused 50% inhibition of the spontaneously developed tension
  • reaction mixture was recooled to -78 C lithium diisopropylamide (4ml, 1.5M in tetrahydrofuran) added, the mixture stirred at -78 C for 30 minutes and at 0°C for 30 minutes.
  • the reaction mixture was quenched with 2N hydrochloric acid (20ml), diluted with ethyl acetate (200ml) and the organic separated, washed with water (2 ⁇ 50ml), dried (MgSO4) and solvent removed at reduced pressure.
  • Column chromatography (silica,
  • dimethylformamide (80ml) was heated at 130°C for 16 hours.
  • the mixture was cooled to room temperature, diluted with ethyl acetate (300ml), washed with water (6 ⁇ 200ml), dried (MgSO 4 ) and solvent removed at reduced pressure.
  • the residue was dissolved in dimethylformamide (80ml), sodium methoxide (10.8g) and cyanoacetamide (8.4g) added and the mixture heated at 120°C until gas evolution ceased (about 1 hour). After pouring into 10% aqueous acetic acid (300ml), the precipitated 6-(4-bromophenyl)-3-cyanopyridin-2(1H)-one
  • compositions for oral administration are prepared by combining the following :
  • the formulations are then filled into individual soft gelatin capsules.
  • a pharmaceutical composition for parenteral administration is prepared by dissolving the title compound of Example 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

On décrit des composés de formule (1) ou un sel pharmaceutiquement acceptable où R0 représente OH ou l'un de ses bioprécurseurs, R1 représente A0CO2H, P(Z)(OH)(OR2), SO2H ou SO3H ou l'un de ses bioprécurseurs, et A0 représente CH¿2?, CHF, CF2, CR?3(OR4¿), CO ou C(OR?5)(OR6?). Ils constituent des agonistes d'une protéine kinase dépendante de l'AMP cyclique et sont utiles comme médicaments.
PCT/GB1992/002117 1991-11-20 1992-11-16 Derives du 2-pyridinol et leur utilisation comme medicaments WO1993010093A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP5509093A JPH07501069A (ja) 1991-11-20 1992-11-16 ２−ピリジノール誘導体およびその医薬的使用
EP92923485A EP0613467A1 (fr) 1991-11-20 1992-11-16 Derives du 2-pyridinol et leur utilisation comme medicaments

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919124577A GB9124577D0 (en) 1991-11-20 1991-11-20 Chemical compounds
GB9124577.9 1991-11-20

Publications (1)

Publication Number Publication Date
WO1993010093A1 true WO1993010093A1 (fr) 1993-05-27

Family

ID=10704880

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1992/002117 WO1993010093A1 (fr) 1991-11-20 1992-11-16 Derives du 2-pyridinol et leur utilisation comme medicaments

Country Status (10)

Country Link
EP (1) EP0613467A1 (fr)
JP (1) JPH07501069A (fr)
AU (1) AU2927792A (fr)
CA (1) CA2124001A1 (fr)
GB (1) GB9124577D0 (fr)
MX (1) MX9206711A (fr)
PT (1) PT101071A (fr)
TW (1) TW221991B (fr)
WO (1) WO1993010093A1 (fr)
ZA (1) ZA928892B (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0428268A2 (fr) * 1989-10-13 1991-05-22 Smith Kline & French Laboratories Limited Dérivés de phénylpyridone pharmaceutiques
WO1991017987A1 (fr) * 1990-05-21 1991-11-28 Smith Kline & French Laboratories Limited Derives de phenol et de pyridinol comme agents pharmaceutiques
WO1992006085A1 (fr) * 1990-09-28 1992-04-16 Smith Kline & French Laboratories Limited Derives de phenylpyridinol utilises comme medicaments

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60122402A (ja) * 1983-12-05 1985-06-29 Komatsu Ltd 信号発生装置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0428268A2 (fr) * 1989-10-13 1991-05-22 Smith Kline & French Laboratories Limited Dérivés de phénylpyridone pharmaceutiques
WO1991017987A1 (fr) * 1990-05-21 1991-11-28 Smith Kline & French Laboratories Limited Derives de phenol et de pyridinol comme agents pharmaceutiques
WO1992006085A1 (fr) * 1990-09-28 1992-04-16 Smith Kline & French Laboratories Limited Derives de phenylpyridinol utilises comme medicaments

Also Published As

Publication number Publication date
EP0613467A1 (fr) 1994-09-07
MX9206711A (es) 1993-05-01
AU2927792A (en) 1993-06-15
CA2124001A1 (fr) 1993-05-27
ZA928892B (en) 1994-05-18
GB9124577D0 (en) 1992-01-08
JPH07501069A (ja) 1995-02-02
TW221991B (fr) 1994-04-01
PT101071A (pt) 1994-02-28

Similar Documents

Publication Publication Date Title
AU644016B2 (en) Phenylpyridinol derivatives as medicaments
AU642743B2 (en) Phenol and pyridinol derivatives as pharmaceuticals
CZ373096A3 (en) Trisubstituted phenyl derivatives, process of their preparation and pharmaceutical compositions containing thereof
NO862208L (no) Fremgangsmaate fpr fremstilling av heterocykliske forbindelser.
KR20190086673A (ko) Sgk 활성을 조절하기 위한 화합물 및 약학 조성물 및 이의 방법
AU2930392A (en) 3-pyridinol derivatives and their use as medicaments
US4863933A (en) 3-hydroxypyridines
CN109912571A (zh) 具有生物活性的新型苯并喹啉取代三氮唑类化合物及其合成方法和应用
WO1993010093A1 (fr) Derives du 2-pyridinol et leur utilisation comme medicaments
US5670493A (en) Aminophenylphosphonic acid compounds
AU654051B2 (en) Pyridinol derivatives as medicaments
WO1993010107A1 (fr) Derives de phenol utilises comme agonistes d'une proteine-kinase cyclique dependant de l'amp
EP0095152B1 (fr) Procédé pour la préparation de nicotinonitriles et produits intermédiaires utilisés dans ce procédé
WO1993022285A1 (fr) Antagonistes de leucotrienes
EP0931790A2 (fr) Procédé pour la préparation de dérivées de 2-sulfonylpyridine et de dérivés de 2-( (2-pyridyl)méthyl)thio)-1H-benzimidazole

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1992923485

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1994 244156

Country of ref document: US

Date of ref document: 19940517

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2124001

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1992923485

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992923485

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载